BRPI0807597A2 - Composição farmacêutica, e, método para tratar infecção por vírus da influenza - Google Patents
Composição farmacêutica, e, método para tratar infecção por vírus da influenzaInfo
- Publication number
- BRPI0807597A2 BRPI0807597A2 BRPI0807597-2A2A BRPI0807597A BRPI0807597A2 BR PI0807597 A2 BRPI0807597 A2 BR PI0807597A2 BR PI0807597 A BRPI0807597 A BR PI0807597A BR PI0807597 A2 BRPI0807597 A2 BR PI0807597A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- influenza virus
- virus infection
- treating influenza
- treating
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 241000712461 unidentified influenza virus Species 0.000 title 1
- 230000009385 viral infection Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007-035975 | 2007-02-16 | ||
| JP2007035975 | 2007-02-16 | ||
| PCT/JP2008/052425 WO2008099874A1 (ja) | 2007-02-16 | 2008-02-14 | ピラジン誘導体を含有する医薬組成物およびピラジン誘導体を組み合わせて使用する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0807597A2 true BRPI0807597A2 (pt) | 2014-05-06 |
| BRPI0807597B1 BRPI0807597B1 (pt) | 2021-03-02 |
| BRPI0807597B8 BRPI0807597B8 (pt) | 2021-05-25 |
Family
ID=39690101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0807597A BRPI0807597B8 (pt) | 2007-02-16 | 2008-02-14 | composição farmacêutica, e, uso de um derivado de pirazina ou um sal do mesmo e um ou mais inibidor(es) de neuraminidase em combinação |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8759354B2 (pt) |
| EP (1) | EP2123276B1 (pt) |
| JP (1) | JP5255456B2 (pt) |
| KR (1) | KR101479083B1 (pt) |
| CN (1) | CN101610772B (pt) |
| AU (1) | AU2008215397B2 (pt) |
| BR (1) | BRPI0807597B8 (pt) |
| CA (1) | CA2677905C (pt) |
| CY (1) | CY1113435T1 (pt) |
| DK (1) | DK2123276T3 (pt) |
| ES (1) | ES2396595T3 (pt) |
| HR (1) | HRP20130111T1 (pt) |
| IL (1) | IL200285A (pt) |
| MX (1) | MX2009008779A (pt) |
| NZ (1) | NZ578989A (pt) |
| PL (1) | PL2123276T3 (pt) |
| PT (1) | PT2123276E (pt) |
| RU (1) | RU2463051C2 (pt) |
| SI (1) | SI2123276T1 (pt) |
| WO (1) | WO2008099874A1 (pt) |
| ZA (1) | ZA200905536B (pt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010117114A1 (en) * | 2009-04-09 | 2010-10-14 | Lg Electronics Inc. | Display apparatus |
| DK2568976T3 (en) * | 2010-05-10 | 2016-01-11 | Academia Sinica | Zanamivir-phosphonate congener with the anti-influenza activity, and determining the sensitivity oseltamivir in influenza viruses |
| US20130217708A1 (en) | 2010-09-30 | 2013-08-22 | Toyama Chemical Co., Ltd. | Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide |
| RS54408B1 (sr) | 2010-09-30 | 2016-04-28 | Toyama Chemical Co. Ltd. | Natrijumova so 6-fluor-3-hidroksi-2-pirazin karboksamida |
| AT510585B1 (de) | 2010-11-18 | 2012-05-15 | Apeptico Forschung & Entwicklung Gmbh | Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase |
| AU2014265483B2 (en) * | 2013-05-14 | 2018-08-02 | Biocryst Pharmaceuticals, Inc. | Anti-influenza compositions and methods |
| CN104447585B (zh) * | 2014-11-20 | 2016-08-24 | 广东东阳光药业有限公司 | 吡嗪类化合物及其组合物及用途 |
| CN104447583B (zh) * | 2014-11-20 | 2016-08-24 | 广东东阳光药业有限公司 | 含有环丁烷取代基的吡嗪类化合物及其组合物及用途 |
| CN104447584B (zh) * | 2014-11-20 | 2016-08-24 | 广东东阳光药业有限公司 | 含有环丁烷取代基的吡嗪类化合物及其组合物及用途 |
| CN104402833B (zh) * | 2014-11-20 | 2016-08-24 | 广东东阳光药业有限公司 | 含有环丁烷取代基的吡嗪类化合物及其组合物及用途 |
| CN104496918B (zh) * | 2014-12-10 | 2016-08-24 | 广东东阳光药业有限公司 | 吡嗪衍生物及其用途 |
| CN104817511B (zh) * | 2015-04-27 | 2017-04-19 | 济南大学 | 一种丁烯二酸酐制备法匹拉韦关键中间体的方法 |
| HK1254961A1 (en) * | 2015-12-15 | 2019-08-02 | Shionogi & Co., Ltd. | Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug |
| WO2020138067A1 (ja) | 2018-12-25 | 2020-07-02 | 富士フイルム富山化学株式会社 | ピラジン誘導体と細胞内におけるピラジン誘導体リボース三リン酸体の量を増加させる化合物とを組み合わせてなるｒｎａウイルス感染症治療剤 |
| EP4144353A4 (en) * | 2020-04-30 | 2024-08-28 | FUJIFILM Toyama Chemical Co., Ltd. | THERAPEUTIC AGENT AGAINST CORONAVIRUS INFECTION FORMED BY COMBINATION OF A PYRAZINE DERIVATIVE AND ANOTHER THERAPEUTIC DRUG AGAINST CORONAVIRUS INFECTION |
| US20230201238A1 (en) | 2020-05-27 | 2023-06-29 | Fujifilm Toyama Chemical Co., Ltd. | Therapeutic agent for an rna virus infection comprising a combination of a pyrazine derivative and a thiopurine derivative |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01197437A (ja) | 1988-01-29 | 1989-08-09 | Dso Pharmachim | 抗ウイルス薬 |
| DK1112743T3 (da) * | 1998-08-20 | 2007-11-26 | Toyama Chemical Co Ltd | Nitrogenholdige heterocykliske carboxamidderivater eller salte deraf som antivirale midler |
| CA2456292A1 (en) | 2001-08-14 | 2003-02-27 | Toyama Chemical Co., Ltd. | Novel virus growth inhibitor and/or virucidal method, and novel pyrazine nucleotide or pirazine nucleoside analog |
| JP2005354833A (ja) * | 2004-06-11 | 2005-12-22 | Fujinon Corp | アクチュエータ |
| JP4689989B2 (ja) * | 2004-08-27 | 2011-06-01 | オリンパス株式会社 | 振動波リニアモータ及びそれを用いたレンズ装置 |
| DE102008031715A1 (de) | 2008-07-04 | 2010-01-07 | Henkel Ag & Co. Kgaa | Haarkonditionierende Mittel mit Imidazolinen |
-
2008
- 2008-02-14 DK DK08711267.8T patent/DK2123276T3/da active
- 2008-02-14 SI SI200830895T patent/SI2123276T1/sl unknown
- 2008-02-14 ZA ZA200905536A patent/ZA200905536B/xx unknown
- 2008-02-14 HR HRP20130111AT patent/HRP20130111T1/hr unknown
- 2008-02-14 AU AU2008215397A patent/AU2008215397B2/en active Active
- 2008-02-14 US US12/527,260 patent/US8759354B2/en active Active
- 2008-02-14 WO PCT/JP2008/052425 patent/WO2008099874A1/ja not_active Ceased
- 2008-02-14 BR BRPI0807597A patent/BRPI0807597B8/pt active IP Right Grant
- 2008-02-14 PT PT87112678T patent/PT2123276E/pt unknown
- 2008-02-14 NZ NZ578989A patent/NZ578989A/en unknown
- 2008-02-14 ES ES08711267T patent/ES2396595T3/es active Active
- 2008-02-14 CA CA2677905A patent/CA2677905C/en active Active
- 2008-02-14 EP EP08711267A patent/EP2123276B1/en active Active
- 2008-02-14 RU RU2009134516/15A patent/RU2463051C2/ru active
- 2008-02-14 JP JP2008558114A patent/JP5255456B2/ja active Active
- 2008-02-14 KR KR20097017506A patent/KR101479083B1/ko active Active
- 2008-02-14 PL PL08711267T patent/PL2123276T3/pl unknown
- 2008-02-14 CN CN200880005061XA patent/CN101610772B/zh active Active
- 2008-02-14 MX MX2009008779A patent/MX2009008779A/es active IP Right Grant
-
2009
- 2009-08-06 IL IL200285A patent/IL200285A/en not_active IP Right Cessation
-
2012
- 2012-12-03 CY CY20121101175T patent/CY1113435T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2463051C2 (ru) | 2012-10-10 |
| CN101610772A (zh) | 2009-12-23 |
| HRP20130111T1 (hr) | 2013-02-28 |
| JP5255456B2 (ja) | 2013-08-07 |
| CN101610772B (zh) | 2013-01-16 |
| BRPI0807597B8 (pt) | 2021-05-25 |
| CA2677905C (en) | 2015-03-24 |
| DK2123276T3 (da) | 2013-01-02 |
| EP2123276A4 (en) | 2011-05-18 |
| KR101479083B1 (ko) | 2015-01-07 |
| US20100087447A1 (en) | 2010-04-08 |
| CA2677905A1 (en) | 2008-08-21 |
| EP2123276B1 (en) | 2012-11-28 |
| AU2008215397A1 (en) | 2008-08-21 |
| IL200285A0 (en) | 2010-04-29 |
| JPWO2008099874A1 (ja) | 2010-05-27 |
| WO2008099874A1 (ja) | 2008-08-21 |
| US8759354B2 (en) | 2014-06-24 |
| PL2123276T3 (pl) | 2013-04-30 |
| SI2123276T1 (sl) | 2013-03-29 |
| EP2123276A1 (en) | 2009-11-25 |
| KR20090121289A (ko) | 2009-11-25 |
| BRPI0807597B1 (pt) | 2021-03-02 |
| MX2009008779A (es) | 2009-11-05 |
| NZ578989A (en) | 2011-07-29 |
| RU2009134516A (ru) | 2011-03-27 |
| AU2008215397B2 (en) | 2012-09-06 |
| PT2123276E (pt) | 2013-01-16 |
| ES2396595T3 (es) | 2013-02-22 |
| CY1113435T1 (el) | 2016-06-22 |
| ZA200905536B (en) | 2010-10-27 |
| IL200285A (en) | 2014-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0815057A2 (pt) | Composto, composição farmacêutica, e, método para tratar infecção. | |
| BRPI0916235A2 (pt) | composto, composição farmacêutica, uso do composto ou da composição, e, método para tratar um paciente infectado com hcv | |
| BRPI0814300A2 (pt) | Composto, composição farmacêutica, e, método para tratar uma infecção viral | |
| BRPI0814939A2 (pt) | Entidade química, composição farmacêutica, e, método para tratar uma infecção viral em um mamífero. | |
| BRPI1013394A2 (pt) | "composto, composição farmacêutica, uso do composto, e, método para tratar um paciente infectado com virus da hepatite c." | |
| BRPI0820578A2 (pt) | Vírus da varíola, processo para preparar um vírus da varíola, composição, uso de um vírus da varíola ou de uma composição, e, método para tratar doenças | |
| BRPI1014322A2 (pt) | Método para tratar infecção, e para interromper ou evitar a produção de partículas virais infecciosas, combinação, e, composição farmacêutica. | |
| BRPI1013640A2 (pt) | composicao farmaceutica, metodos para o tratamento e usos dos mesmos | |
| BRPI0906804A2 (pt) | Método para liofilizar partículas, e, acondicionamento farmacêutico | |
| BR112012018951A2 (pt) | composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo | |
| BRPI0917458A2 (pt) | composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto | |
| BRPI0815387A2 (pt) | composição farmacêutica, método para fazer uma composição farmacêutica e método de tratar uma condição | |
| BRPI0922475A2 (pt) | composto, composição farmacêutica , método para tratar câncer, e, uso de um composto. | |
| BRPI0907977A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
| BRPI0819218A2 (pt) | Métodos, estojos e composições para administração de compostos farmacêuticos | |
| BR112013015010A2 (pt) | produto, substrato, composição farmacêutica, uso de um produto, e, método para tratar uma infecção microbiana | |
| BRPI0811589A2 (pt) | Composição farmacêutica e método para tratar câncer | |
| BR112012004333A2 (pt) | composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio. | |
| BR112013010738A2 (pt) | composto, composição farmacêutica, e, método para tratar uma infecção viral | |
| BRPI1015983A2 (pt) | composto, uso do composto, método para tratar um paciente, e, composição farmacêutica. | |
| BRPI0908635A2 (pt) | composto, composição farmacêutica e método de tratamento de câncer | |
| EP2497482A4 (en) | COMPOSITION FOR PROPHYLAXIS AND TREATMENT OF INFLUENZA AVIRUSED INDUCED DISEASES | |
| BRPI1013396A2 (pt) | composto, produto farmacêutico de combinação, uso de um composto, método para tratar uma doença ou condição, e, processo para a preparação de um composto. | |
| BRPI0907974A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
| IL202450A (en) | Pharmaceutical composition to treat influenza virus infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: FUJIFILM TOYAMA CHEMICAL CO., LTD. (JP) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/03/2021, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/02/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |